Lilly's revenue soars 48%, driven by demand of its GLP-1s

Its sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.

Source: Market Watch

Visit Source

0 0 0

Comment

Important Notice: More than 48 hours have passed since this news or analysis was published. Due to the volatility of financial markets, some of the information or data presented may no longer be valid or reflect current market conditions. Please verify the information again before making any trading or investment decisions.

Comments

No comments yet

Be the first person to comment on this news item.

Category General

Source Market Watch

Published 2 months ago

Likes 0

Comments 0

Shares 0

News ID #837

Status Published

This news may have been collected automatically from third-party sources. Please verify important information through the original source and other reliable sources before making any trading or investment decision. This content is provided for informational purposes only and does not constitute financial advice.

Keep comments relevant to the news topic and avoid offensive, promotional, spam, or misleading content.